Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulfonylurea continuation versus discontinuation with metformin plus insulin glargine in insulin-naive type 2 diabetes
NL-OMON27312Active, not recruiting
- Sponsor
- Julius Clinical
- Start
- Apr 2006
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of insulin glargine and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Julius Clinical. Primary endpoint: Remaining beta-cell insulin secretion. Started Apr 2006; status: active, not recruiting.
02
Drugs
insulin glarginemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON27312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27312.